このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Alterity Therapeutics 将来の成長

Future 基準チェック /06

Alterity Therapeuticsの収益と利益は、それぞれ年間7.5%と11.4%減少すると予測されています。

主要情報

-11.4%

収益成長率

n/a

EPS成長率

Biotechs 収益成長	15.0%
収益成長率	-7.5%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	15 May 2024

今後の成長に関する最新情報

更新なし

Recent updates

Shareholders May Be More Conservative With Alterity Therapeutics Limited's (ASX:ATH) CEO Compensation For Now

Nov 23

業績と収益の成長予測

ASX:ATH - アナリストの将来予測と過去の財務データ ( )AUD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
6/30/2027	1	-20	N/A	N/A	1
6/30/2026	4	-19	0	-20	2
6/30/2025	6	-17	-8	-18	2
6/30/2024	4	-19	-17	-17	1
12/31/2023	3	-12	-15	-15	N/A
9/30/2023	4	-13	-17	-17	N/A
6/30/2023	4	-14	-20	-20	N/A
3/31/2023	5	-14	-17	-17	N/A
12/31/2022	5	-14	-14	-14	N/A
9/30/2022	5	-14	-13	-13	N/A
6/30/2022	5	-13	-12	-12	N/A
3/31/2022	5	-13	-16	-16	N/A
12/31/2021	5	-13	-19	-19	N/A
9/30/2021	5	-14	-18	-18	N/A
6/30/2021	4	-15	-17	-17	N/A
3/31/2021	2	-16	-16	-16	N/A
12/31/2020	0	-16	-14	-14	N/A
9/30/2020	0	-15	-12	-12	N/A
6/30/2020	N/A	-13	-9	-9	N/A
3/31/2020	2	-13	-9	-9	N/A
12/31/2019	4	-13	-9	-9	N/A
9/30/2019	5	-12	-12	-12	N/A
6/30/2019	5	-12	-14	-14	N/A
3/31/2019	5	-11	-13	-13	N/A
12/31/2018	4	-10	-12	-12	N/A
9/30/2018	4	-9	-9	-9	N/A
6/30/2018	3	-8	-6	-6	N/A
3/31/2018	3	-8	-6	-6	N/A
12/31/2017	3	-8	-6	-6	N/A
9/30/2017	3	-8	N/A	-6	N/A
6/30/2017	3	-8	N/A	-6	N/A
3/31/2017	4	-8	N/A	-3	N/A
12/31/2016	4	-9	N/A	-1	N/A
9/30/2016	4	-8	N/A	-4	N/A
6/30/2016	5	-8	N/A	-7	N/A
3/31/2016	5	-8	N/A	-9	N/A
12/31/2015	6	-7	N/A	-10	N/A
9/30/2015	6	-7	N/A	-10	N/A
6/30/2015	6	-6	N/A	-11	N/A
3/31/2015	8	-6	N/A	-13	N/A
12/31/2014	10	-7	N/A	-15	N/A
9/30/2014	9	-10	N/A	-14	N/A
6/30/2014	8	-13	N/A	-14	N/A
3/31/2014	6	-12	N/A	-12	N/A
12/31/2013	4	-11	N/A	-11	N/A
9/30/2013	4	-10	N/A	-9	N/A

アナリストによる今後の成長予測

収入対貯蓄率: ATH今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: ATH今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: ATH今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: ATHの収益は今後 3 年間で減少すると予想されています (年間-7.5% )。

高い収益成長: ATHの収益は今後 3 年間で減少すると予測されています (年間-7.5% )。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ATHの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Alterity Therapeutics 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Recent updates

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review

Alterity Therapeutics Limited Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Diseases

Alterity Therapeutics Limited has filed a Follow-on Equity Offering in the amount of $6 million.

Alterity Therapeutics's Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review

Alterity Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 4.8 million.

Alterity Therapeutics Limited Announces CFO Changes

Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson's Disease

New minor risk - Shareholder dilution

Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System Atrophy

Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System Atrophy

Alterity Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 4.8 million.

Shareholders May Be More Conservative With Alterity Therapeutics Limited's (ASX:ATH) CEO Compensation For Now

Alterity Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million.

Alterity Therapeutics Completes Enrolment in Ath434-201 Phase 2 Clinical Trial in Multiple System Atrophy

Alterity Therapeutics Completes Enrolment in Ath434-201 Phase 2 Clinical Trial in Multiple System Atrophy

New major risk - Market cap size

Alterity Therapeutics Limited, Annual General Meeting, Nov 29, 2023

New minor risk - Financial data availability

Alterity Therapeutics Limited Grants New Composition of Matter Patent in Europe for Neurodegenerative Diseases Including Parkinson's and Alzheimer's

Alterity Therapeutics Limited Announces an Independent Data Monitoring Committee Recommends the ATH434-201 Phase 2 Study

Alterity Therapeutics Initiates Second Phase 2 Study in Rare Parkinsonian Disorder

Alterity Therapeutics Enrolls First Patient in Australia in Ath434 Global Phase 2 Clinical Trial in Multiple System Atrophy

Alterity Therapeutics Limited Receives Regulatory Approval for Phase II Trial in France and Austria

Alterity Therapeutics Limited Announces A Study Recently Published in the Journal Neurotherapeutics Demonstrated Its Lead Clinical Asset, Ath34, Was Neuroprotective in A Genetic Model of Parkinson's Disease

Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Italy for the Treatment of Individuals with Multiple System Atrophy

Alterity Therapeutics Limited Launches ATH434 Phase 2 Clinical Trial in the United States for the Treatment of Individuals with Multiple System Atrophy

Alterity Therapeutics Limited Announces A New Composition of Matter Patent Allowed by the United States Patent and Trademark Office

Insufficient new directors

Alterity Therapeutics Announces Presentation of MRI Data from the bioMUSE Natural History Study at the American Neurological Association Annual Meeting

Alterity Therapeutics Limited, Annual General Meeting, Nov 11, 2022

Alterity Therapeutics Announces Presentation of Wearable Sensor Data from the Biomuse Natural History Study At the International Congress of Parkinson's Disease and Movement Disorders

Alterity Therapeutics Receives U.S. FDA Approval for Investigational New Drug Application for ATH434 for the Treatment of Multiple System Atrophy

Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy in Europe

Alterity Therapeutics Limited Doses First Patient in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy

We're Keeping An Eye On Alterity Therapeutics' (ASX:ATH) Cash Burn Rate

Alterity Therapeutics Limited Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in Italy

Alterity Therapeutics Limited Launches ATH434 Phase 2 Clinical Trial

Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in the United Kingdom

Insufficient new directors

Alterity Therapeutics Announces Presentation of bioMUSE Data at the American Academy of Neurology (AAN) Annual Meeting

Is Alterity Therapeutics (ASX:ATH) In A Good Position To Invest In Growth?

Alterity Therapeutics Announces Publication Demonstrating ATH434 Is Neuroprotective in Animal Model of Parkinsonian Disorder in the Journal of Parkinson’s Disease

Alterity Therapeutics Granted New US Patent for Compounds for Neurodegenerative Diseases Including Parkinson’S and Alzheimer’S

Alterity Therapeutics Limited Announces First Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial

Alterity Therapeutics Announces Data Was Presented from the Company’s Biomarkers of Progression in Multiple System Atrophy Study

United States Patent and Trademark Office Issues Notice of Allowance for Patent Application of Alterity Therapeutics to Expand its Portfolio of Compounds for Neurodegenerative Diseases Including Alzheimer's and Parkinson's

Alterity Therapeutics Limited Announces New Publication Demonstrates ATH434 Is Neuroprotective

Alterity Therapeutics Limited announced that it has received AUD 17.17604 million in funding

Alterity Therapeutics Granted Anew Us Patent Targeting Major Neurodegenerative Diseases Including Alzheimer's and Parkinson's

Alterity Therapeutics Limited Received European Union Regulatory Guidance for ATH434 Phase 2 Clinical Trial

We're Hopeful That Alterity Therapeutics (ASX:ATH) Will Use Its Cash Wisely

Alterity Therapeutics Limited to Report First Half, 2021 Results on Feb 25, 2021

Here's Why We're Watching Alterity Therapeutics' (ASX:ATH) Cash Burn Situation

Alterity Therapeutics Limited Appoints Dr. David Stamler as CEO

How Much Is Alterity Therapeutics Limited (ASX:ATH) CEO Getting Paid?

Alterity Announces Approval of US Patent for Next Generation Compounds to Treat Neurodegenerative Diseases

Alterity Therapeutics Commences Enrolling Multiple System Atrophy Patients in bioMUSE Study

Alterity Therapeutics Limited announced that it expects to receive AUD 35 million in funding

Alterity Therapeutics Limited Auditor Raises 'Going Concern' Doubt

Alterity Therapeutics Limited to Report Fiscal Year 2020 Results on Sep 09, 2020

Full year earnings released - AU$0.011 loss per share

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘